MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
about
A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapyMicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications.Screening of potential biomarkers for chemoresistant ovarian carcinoma with miRNA expression profiling data by bioinformatics approach.MiRNA profiling of whole trabecular bone: identification of osteoporosis-related changes in MiRNAs in human hip bones.MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagyProfile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma.miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.Tumour-suppressor microRNAs regulate ovarian cancer cell physical properties and invasive behaviour.Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.microRNA deregulation in keloids: an opportunity for clinical intervention?microRNA and Ovarian Cancer.Current status on microRNAs as biomarkers for ovarian cancer.MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.CCAT1: a pivotal oncogenic long non-coding RNA in human cancers.miR-200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E-box-binding homeobox 2 (ZEB2) expression.miR-320 inhibited ovarian cancer oncogenicity via targeting TWIST1 expression.miR-509-5p inhibits cellular proliferation and migration via targeting MDM2 in pancreatic cancer cells.MiR-448 promotes vascular smooth muscle cell proliferation and migration in through directly targeting MEF2C.Role of miR-483 in digestive tract cancers: from basic research to clinical value.Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer.The Glucose-Regulated MiR-483-3p Influences Key Signaling Pathways in Cancer.Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network
P2860
Q28543958-8AED30FF-60AF-4FE2-9C25-2D27108BF0D3Q30244282-03CB5291-25D8-418F-9086-130C5052ABF2Q31029533-6D6BA680-D405-4E63-B2D7-1A12A8D98781Q35837272-B152D204-A7DB-486E-A71D-88E1E0AF7F66Q36370545-72C2E868-0651-48D3-B70E-6E1A00EF4F50Q36592537-596280E0-CBFB-4EF9-8147-3B70199275B1Q37104731-910E4A1F-2F28-4A8D-B2E4-B79D58196996Q37295543-2C602E4B-5EE0-4774-9FD8-CB5023C2F9C7Q37464162-F53E0839-3D37-4DB3-A20A-EEE947A64EFCQ38258014-0EBD3BA5-C3FE-4147-BCF4-D85F89198DB3Q38612431-58FF8D81-826E-4221-84DB-08EABA4435BCQ38667018-EE2B990B-7CC7-485F-AB4B-5F48ECFE0CB1Q38711390-12353764-5BD5-441E-8B65-AB6A2E9ABD30Q38814833-F65D91DA-B017-489A-9434-B40E55D8EA56Q38819843-FE5176D2-6890-4192-882D-8330B0A62AE7Q38822607-BDA41079-BA21-4460-8353-77D109BBAB11Q38972688-8C729747-4BB2-47CB-9AAB-231803C73EEAQ41549337-35CA520A-CC88-44F7-BF94-1922ABE2160DQ42359987-96F67C1A-D998-4840-BCFF-C4D24DE1BFAEQ47965519-3B5C3039-63BD-45F4-8B7F-E6E8B00C8298Q49313057-8BDC8FD5-C197-4BB1-93B1-CC36E1D7FB37Q51516305-06EEBAE3-6DCF-4393-99B6-2ED60E0FCA8BQ55483353-8CFE4078-F270-425D-AFA8-62086A7304FCQ58742926-71EEF766-8D0C-4A36-B711-702DD97B022B
P2860
MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
MiRNA expression signature for ...... s of ovarian serous carcinoma.
@en
MiRNA expression signature for ...... s of ovarian serous carcinoma.
@nl
type
label
MiRNA expression signature for ...... s of ovarian serous carcinoma.
@en
MiRNA expression signature for ...... s of ovarian serous carcinoma.
@nl
prefLabel
MiRNA expression signature for ...... s of ovarian serous carcinoma.
@en
MiRNA expression signature for ...... s of ovarian serous carcinoma.
@nl
P2093
P2860
P1433
P1476
MiRNA expression signature for ...... s of ovarian serous carcinoma.
@en
P2093
Chang Wang
Gordon Guo
Jinyao Zhao
Jiyong Jiang
Shiying Cui
Tingting Jia
Xiaotang Yu
P2860
P2888
P304
P356
10.1007/S13277-013-0928-3
P577
2013-07-09T00:00:00Z
P6179
1016936728